This reports provides a data-driven overview of the current and future competitive landscape in Influenza Prophylactics therapeutics.
Across the 16 major markets, there were over 540 million individuals vaccinated against influenza in 2022.
Globally, a high number of vaccines are approved and marketed for the prevention of influenza; AstraZeneca, Sanofi, and GSK are the top key players in this space.
R&D activity within the influenza prophylactics space is highly active, with 18 products in late-stage development across the 16 major markets.
Moderna currently dominates clinical trial development in influenza, with the US emerging as the key country for conducting trials in influenza.
Deals involving partnerships are the most common type of deals in the US and Europe among companies involved in developing influenza assets.
One regulatory filing/commercial launch is expected in the US during the next 18 months, for Novavax's NanoFlu.
Across the 16 major markets, there were over 540 million individuals vaccinated against influenza in 2022.
Globally, a high number of vaccines are approved and marketed for the prevention of influenza; AstraZeneca, Sanofi, and GSK are the top key players in this space.
R&D activity within the influenza prophylactics space is highly active, with 18 products in late-stage development across the 16 major markets.
Moderna currently dominates clinical trial development in influenza, with the US emerging as the key country for conducting trials in influenza.
Deals involving partnerships are the most common type of deals in the US and Europe among companies involved in developing influenza assets.
One regulatory filing/commercial launch is expected in the US during the next 18 months, for Novavax's NanoFlu.
Scope
The publisher's Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Influenza Prophylactics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Influenza Prophylactics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
5.1 Annual Therapy Cost
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Geographic Overview
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
11.1 Methodology
11.2 Methodology - Sales Forecast
11.3 Methodology - Pricing and Reimbursement
11.4 Methodology - PTSR and LoA Analysis
11.5 About the Authors
11.6 Contact the Publisher
11.7 Disclaimer
